# A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease

> **NCT06164730** · PHASE1 · RECRUITING · sponsor: **Verve Therapeutics, Inc.** · enrollment: 85 (estimated)

## Conditions studied

- Heterozygous Familial Hypercholesterolemia
- Premature Coronary Heart Disease

## Interventions

- **DRUG:** VERVE-102

## Key facts

- **NCT ID:** NCT06164730
- **Lead sponsor:** Verve Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-30
- **Primary completion:** 2026-08
- **Final completion:** 2027-08
- **Target enrollment:** 85 (ESTIMATED)
- **Last updated:** 2026-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06164730

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06164730, "A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06164730. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*